BMI category-specific waist circumference thresholds based on cardiovascular disease outcomes and all-cause mortality: Tehran lipid and glucose study (TLGS).


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
05 07 2023
Historique:
received: 02 10 2022
accepted: 26 06 2023
medline: 7 7 2023
pubmed: 6 7 2023
entrez: 5 7 2023
Statut: epublish

Résumé

Waist circumference (WC), a representative of abdominal visceral fat, is strongly associated with cardiovascular disease (CVD) and its outcomes. We aimed to define body mass index (BMI)-specific WC thresholds as predictors of CVD and all-cause mortality. In this prospective cohort study in the context of the Tehran Lipid and Glucose Study (TLGS), a total of 3344 men and 4068 women were followed up for 18 years. Based on BMI, the participants were categorized into three groups: BMI < 25, 25 < BMI < 30, and BMI > 30. In each BMI category, sex-specific WC thresholds were estimated by the maximum value of Youden's index to predict based on incident CVD events and all-cause mortality prediction. Overall 667 and 463 CVD events (the incidence rate of 3.1 to 4.5 in men and 1.1 to 2.6 in women per 1,000 person-years within BMI categories) and 438 and 302 mortalities (the incidence rate of 2.1 to 2.7 in men and 1.2 to 1.4 in women per 1,000 person-years within BMI categories) were recorded in men and women, respectively. WC thresholds in the BMI categories of < 25, 25-30, and BMI > 30 kg/m BMI-specific WC thresholds observed here can help to better identify individuals at high risk of developing CVDs.

Sections du résumé

BACKGROUND
Waist circumference (WC), a representative of abdominal visceral fat, is strongly associated with cardiovascular disease (CVD) and its outcomes. We aimed to define body mass index (BMI)-specific WC thresholds as predictors of CVD and all-cause mortality.
METHODS
In this prospective cohort study in the context of the Tehran Lipid and Glucose Study (TLGS), a total of 3344 men and 4068 women were followed up for 18 years. Based on BMI, the participants were categorized into three groups: BMI < 25, 25 < BMI < 30, and BMI > 30. In each BMI category, sex-specific WC thresholds were estimated by the maximum value of Youden's index to predict based on incident CVD events and all-cause mortality prediction.
RESULTS
Overall 667 and 463 CVD events (the incidence rate of 3.1 to 4.5 in men and 1.1 to 2.6 in women per 1,000 person-years within BMI categories) and 438 and 302 mortalities (the incidence rate of 2.1 to 2.7 in men and 1.2 to 1.4 in women per 1,000 person-years within BMI categories) were recorded in men and women, respectively. WC thresholds in the BMI categories of < 25, 25-30, and BMI > 30 kg/m
CONCLUSION
BMI-specific WC thresholds observed here can help to better identify individuals at high risk of developing CVDs.

Identifiants

pubmed: 37407928
doi: 10.1186/s12889-023-16190-w
pii: 10.1186/s12889-023-16190-w
pmc: PMC10324109
doi:

Substances chimiques

Lipids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1297

Informations de copyright

© 2023. The Author(s).

Références

Obesity (Silver Spring). 2009 Dec;17(12):2232-8
pubmed: 19360008
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Mayo Clin Proc. 2014 Mar;89(3):335-45
pubmed: 24582192
Int J Obes (Lond). 2012 Nov;36(11):1450-4
pubmed: 22249224
Public Health Nutr. 2014 Apr;17(4):861-9
pubmed: 23481553
BMC Pediatr. 2021 Nov 6;21(1):494
pubmed: 34742260
Diabetes Care. 2005 Jan;28 Suppl 1:S37-42
pubmed: 15618111
Postgrad Med J. 2021 May;97(1147):306-311
pubmed: 32371408
J Am Coll Cardiol. 2001 Nov 1;38(5):1581-3
pubmed: 11691544
Zhonghua Nei Ke Za Zhi. 2006 May;45(5):372-5
pubmed: 16780737
J Clin Epidemiol. 2008 Jul;61(7):646-53
pubmed: 18359190
Eur Heart J. 2013 Feb;34(5):345-53
pubmed: 22947610
Arch Intern Med. 2010 Aug 9;170(15):1293-301
pubmed: 20696950
Int J Obes (Lond). 2009 Dec;33(12):1437-45
pubmed: 19752876
Circulation. 2003 Nov 18;108(20):2543-9
pubmed: 14610011
Eur J Cardiovasc Prev Rehabil. 2009 Dec;16(6):729-34
pubmed: 19809330
Nat Rev Endocrinol. 2020 Mar;16(3):177-189
pubmed: 32020062
Public Health Nutr. 2015 Nov;18(16):2981-9
pubmed: 25711365
Obes Res. 2004 Jul;12(7):1094-103
pubmed: 15292473
Trials. 2009 Jan 25;10:5
pubmed: 19166627
Ups J Med Sci. 2019 Jan;124(1):78-82
pubmed: 30256695
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Diabetes Res Clin Pract. 2008 Oct;82(1):104-7
pubmed: 18706730
J Nutr Health Aging. 2018;22(8):975-981
pubmed: 30272102
Clin J Am Soc Nephrol. 2011 Jul;6(7):1722-30
pubmed: 21734088
Metab Syndr Relat Disord. 2010 Jun;8(3):209-13
pubmed: 20085488
N Engl J Med. 2008 Nov 13;359(20):2105-20
pubmed: 19005195
Am J Kidney Dis. 2011 Aug;58(2):177-85
pubmed: 21601327
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
Obes Facts. 2013;6(4):317-24
pubmed: 23970141
Diabetes Care. 2007 Jun;30(6):1647-52
pubmed: 17360974
Intern Med. 2012;51(2):139-46
pubmed: 22246480
Mayo Clin Proc. 2010 Feb;85(2):112-4
pubmed: 20118385
Obesity (Silver Spring). 2015 Apr;23(4):879-85
pubmed: 25755157
Obes Res Clin Pract. 2017 Jan - Feb;11(1):19-26
pubmed: 27364234
Int J Obes (Lond). 2007 Oct;31(10):1552-3
pubmed: 17549092
Circulation. 2007 Jul 3;116(1):39-48
pubmed: 17576866
Obesity (Silver Spring). 2009 Aug;17(8):1615-20
pubmed: 19265793
J Clin Med. 2019 Jan 10;8(1):
pubmed: 30634601
BMJ. 1995 Jul 15;311(6998):158-61
pubmed: 7613427
Int J Epidemiol. 2012 Jun;41(3):805-17
pubmed: 22467292
Nutr Rev. 1998 Apr;56(4 Pt 1):106-14
pubmed: 9584495
Circulation. 2008 Apr 1;117(13):1658-67
pubmed: 18362231
J Atheroscler Thromb. 2010 May;17(5):468-75
pubmed: 20057171
Arch Intern Med. 2002 Oct 14;162(18):2074-9
pubmed: 12374515

Auteurs

Amirhosein Seyedhoseinpour (A)

Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Maryam Barzin (M)

Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Maryam Mahdavi (M)

Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Majid Valizadeh (M)

Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Fereidoun Azizi (F)

Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Sahar Ghareh (S)

Tehran Branch, Faculty of Medicine, Islamic Azad University, Tehran, Iran.

Farhad Hosseinpanah (F)

Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. fhospanah@endocrine.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH